| Handbook of biologically active peptides A Kastin Academic press, 2013 | 710 | 2013 |
| GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet PL McClean, N Irwin, RS Cassidy, JJ Holst, VA Gault, PR Flatt American Journal of Physiology-Endocrinology and Metabolism 293 (6), E1746-E1755, 2007 | 271 | 2007 |
| Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3) GIP administration improves glucose tolerance and ameliorates insulin resistance and … VA Gault, N Irwin, BD Green, JT McCluskey, B Greer, CJ Bailey, P Harriott, ... Diabetes 54 (8), 2436-2446, 2005 | 191 | 2005 |
| Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 BD Green, N Irwin, NA Duffy, VA Gault, FPM O'harte, PR Flatt European journal of pharmacology 547 (1-3), 192-199, 2006 | 174 | 2006 |
| Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice BD Green, N Irwin, PR Flatt Peptides 28 (5), 981-987, 2007 | 159 | 2007 |
| Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications N Irwin, PR Flatt Diabetologia 52, 1724-1731, 2009 | 145 | 2009 |
| Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat … VA Gault, PL McClean, RS Cassidy, N Irwin, PR Flatt Diabetologia 50, 1752-1762, 2007 | 136 | 2007 |
| Therapeutic potential for GIP receptor agonists and antagonists N Irwin, PR Flatt Best Practice & Research Clinical Endocrinology & Metabolism 23 (4), 499-512, 2009 | 123 | 2009 |
| A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon … VA Gault, VK Bhat, N Irwin, PR Flatt Journal of Biological Chemistry 288 (49), 35581-35591, 2013 | 113 | 2013 |
| Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic … N Irwin, PL McClean, FPM O’harte, VA Gault, P Harriott, PR Flatt Diabetologia 50, 1532-1540, 2007 | 110 | 2007 |
| Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality A Mieczkowska, N Irwin, PR Flatt, D Chappard, G Mabilleau Bone 56 (2), 337-342, 2013 | 105 | 2013 |
| Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor G Mabilleau, A Mieczkowska, N Irwin, PR Flatt, D Chappard J Endocrinol 219 (1), 59-68, 2013 | 94 | 2013 |
| Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice DW Porter, N Irwin, PR Flatt, C Hölscher, VA Gault European journal of pharmacology 650 (2-3), 688-693, 2011 | 87 | 2011 |
| A novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat–fed mice N Irwin, V Pathak, PR Flatt Diabetes 64 (8), 2996-3009, 2015 | 83 | 2015 |
| Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice C Gaudin-Audrain, N Irwin, S Mansur, PR Flatt, B Thorens, M Baslé, ... Bone 53 (1), 221-230, 2013 | 81 | 2013 |
| Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic … R Lennox, DW Porter, PR Flatt, C Holscher, N Irwin, VA Gault Neuropharmacology 86, 22-30, 2014 | 77 | 2014 |
| Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus SA Mansur, A Mieczkowska, B Bouvard, PR Flatt, D Chappard, N Irwin, ... Journal of cellular physiology 230 (12), 3009-3018, 2015 | 75 | 2015 |
| Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival D Khan, S Vasu, RC Moffett, N Irwin, PR Flatt Molecular and cellular endocrinology 436, 102-113, 2016 | 73 | 2016 |
| Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP (1-30) and GIP (1-42) in high-fat fed mice VA Gault, DW Porter, N Irwin, PR Flatt Journal of Endocrinology 208 (3), 265, 2011 | 73 | 2011 |
| Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes V Pathak, PR Flatt, N Irwin Peptides 100, 229-235, 2018 | 71 | 2018 |
